Home » New Findings From REPLACE Study Support Potential of Natpara to Treat Adult Hypoparathyroidism
New Findings From REPLACE Study Support Potential of Natpara to Treat Adult Hypoparathyroidism
NPS Pharmaceuticals announced that new findings from the double-blind, placebo-controlled Phase III REPLACE study of Natpara (recombinant human parathyroid hormone (rhPTH [1-84])) support the drug’s therapeutic potential as the first parathyroid hormone replacement therapy for adults with hypoparathyroidism.
4-Traders
4-Traders
Upcoming Events
-
07May
-
14May
-
30May